Bausch + Lomb launches $1.4B notes offering and $500M term loans to finance XIIDRA acquisition

Bausch & Lomb Corp

$1.4B senior secured notes due 2028 offered via Bausch + Lomb Escrow Corp.; $500M term B loans also planned.
Proceeds to fund acquisition of XIIDRA and other ophthalmology assets, pay fees, and repay existing debt.
Notes offering not conditioned on acquisition close; if not closed by Sept 30, 2024, notes redeemed at principal plus interest.
Purchase price allocation adjusted: prepaid assets reduced $22M, other liabilities cut $12M, goodwill up $10M; no impact on revenue or adjusted EBITDA.
Acquisition expected to close around end of September 2023; term loan facility conditioned on completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.